A Multi-Atlas-Based [18F]9-Fluoropropyl-(+)-Dihydrotetrabenazine Positron Emission Tomography Image Segmentation Method for Parkinson's Disease Quantification

Overview

Journal Front Aging Neurosci

Specialty Geriatrics

Date 2022 Jun 30

PMID 35769601

Authors

Yiwei Pan

Shuying Liu

Yao Zeng

Chenfei Ye

Hongwen Qiao

Tianbing Song

Haiyan Lv

Piu Chan

Jie Lu

Ting Ma

Affiliations

Soon will be listed here.

Abstract

Objectives: [18F]9-fluoropropyl-(+)-dihydrotetrabenazine ([18F]-FP-DTBZ) positron emission tomography (PET) provides reliable information for the diagnosis of Parkinson's disease (PD). In this study, we proposed a multi-atlas-based [18F]-FP-DTBZ PET image segmentation method for PD quantification assessment.

Methods: A total of 99 subjects from Xuanwu Hospital of Capital Medical University were included in this study, and both brain PET and magnetic resonance (MR) scans were conducted. Data from 20 subjects were used to generate atlases, based on which a multi-atlas-based [18F]-FP-DTBZ PET segmentation method was developed especially for striatum and its subregions. The proposed method was compared with the template-based method through striatal subregion parcellation performance and the standard uptake value ratio (SUVR) quantification accuracy. Discriminant analysis between healthy controls (HCs) and PD patients was further performed.

Results: Segmentation results of the multi-atlas-based method showed better consistency than the template-based method with the ground truth, yielding a dice coefficient of 0.81 over 0.73 on the full striatum. The SUVRs calculated by the multi-atlas-based method had an average interclass correlation coefficient (ICC) of 0.953 with the standardized result, whereas the template-based method only reached 0.815. The SUVRs of HCs were generally higher than that of patients with PD and showed significant differences in all of the striatal subregions (all < 0.001). The median and posterior putamen performed best in discriminating patients with PD from HCs.

Conclusion: The proposed multi-atlas-based [18F]-FP-DTBZ PET image segmentation method achieved better performance than the template-based method, indicating great potential in improving accuracy and efficiency for PD diagnosis in clinical routine.

Citing Articles

A systematic review of the challenges, emerging solutions and applications, and future directions of PET/MRI in Parkinson's disease.

Leung I, Strudwick M EJNMMI Rep. 2024; 8(1):3.

PMID: 38748251 PMC: 10962627. DOI: 10.1186/s41824-024-00194-9.

References

Bui V, Hsu L, Shanbhag S, Tran L, Bandettini W, Chang L . Improving multi-atlas cardiac structure segmentation of computed tomography angiography: A performance evaluation based on a heterogeneous dataset. Comput Biol Med. 2020; 125:104019. PMC: 7655721. DOI: 10.1016/j.compbiomed.2020.104019. View

Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang D, Huang Y . Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab. 2003; 23(3):285-300. DOI: 10.1097/01.WCB.0000048520.34839.1A. View

Pirker W, Djamshidian S, Asenbaum S, Gerschlager W, Tribl G, Hoffmann M . Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord. 2002; 17(1):45-53. DOI: 10.1002/mds.1265. View

Alavi A, Werner T, Hoilund-Carlsen P, Zaidi H . Correction for Partial Volume Effect Is a Must, Not a Luxury, to Fully Exploit the Potential of Quantitative PET Imaging in Clinical Oncology. Mol Imaging Biol. 2017; 20(1):1-3. DOI: 10.1007/s11307-017-1146-y. View

Thomas B, Cuplov V, Bousse A, Mendes A, Thielemans K, Hutton B . PETPVC: a toolbox for performing partial volume correction techniques in positron emission tomography. Phys Med Biol. 2016; 61(22):7975-7993. DOI: 10.1088/0031-9155/61/22/7975. View

Mzayek Y, de Ruiter M, Oldenburg H, Reneman L, Schagen S . Measuring decline in white matter integrity after systemic treatment for breast cancer: omitting skeletonization enhances sensitivity. Brain Imaging Behav. 2020; 15(3):1191-1200. PMC: 8286227. DOI: 10.1007/s11682-020-00319-1. View

Hsiao I, Weng Y, Hsieh C, Lin W, Wey S, Kung M . Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography. JAMA Neurol. 2014; 71(6):758-66. DOI: 10.1001/jamaneurol.2014.290. View

Lin K, Lin W, Hsieh C, Weng Y, Wey S, Lu C . Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements. Nucl Med Biol. 2011; 38(8):1149-55. DOI: 10.1016/j.nucmedbio.2011.05.010. View

Chang I, Lue K, Hsieh H, Liu S, Kao C . Automated striatal uptake analysis of ¹⁸F-FDOPA PET images applied to Parkinson's disease patients. Ann Nucl Med. 2011; 25(10):796-803. DOI: 10.1007/s12149-011-0533-8. View

10.

Okamura N, Villemagne V, Drago J, Pejoska S, Dhamija R, Mulligan R . In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J Nucl Med. 2010; 51(2):223-8. DOI: 10.2967/jnumed.109.070094. View

11.

Postuma R, Berg D . The New Diagnostic Criteria for Parkinson's Disease. Int Rev Neurobiol. 2017; 132:55-78. DOI: 10.1016/bs.irn.2017.01.008. View

12.

Rai S, Chaturvedi V, Singh P, Singh B, Singh M . in Parkinson's and in some other diseases: recent advancement and future prospective. 3 Biotech. 2020; 10(12):522. PMC: 7655893. DOI: 10.1007/s13205-020-02532-7. View

13.

Ravina B, Eidelberg D, Ahlskog J, Albin R, Brooks D, Carbon M . The role of radiotracer imaging in Parkinson disease. Neurology. 2005; 64(2):208-15. DOI: 10.1212/01.WNL.0000149403.14458.7F. View

14.

Sun J, Xu J, Cairns N, Perlmutter J, Mach R . Dopamine D1, D2, D3 receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain. PLoS One. 2012; 7(11):e49483. PMC: 3504049. DOI: 10.1371/journal.pone.0049483. View

15.

Fleisher A, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N . Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011; 68(11):1404-11. DOI: 10.1001/archneurol.2011.150. View

16.

Clark C, Schneider J, Bedell B, Beach T, Bilker W, Mintun M . Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011; 305(3):275-83. PMC: 7041965. DOI: 10.1001/jama.2010.2008. View

17.

de Natale E, Niccolini F, Wilson H, Politis M . Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease. Int Rev Neurobiol. 2018; 141:131-172. DOI: 10.1016/bs.irn.2018.08.003. View

18.

Xiao Y, Fonov V, Beriault S, Gerard I, Sadikot A, Pike G . Patch-based label fusion segmentation of brainstem structures with dual-contrast MRI for Parkinson's disease. Int J Comput Assist Radiol Surg. 2014; 10(7):1029-41. DOI: 10.1007/s11548-014-1119-4. View

19.

Staley J, Mash D . Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci. 1996; 16(19):6100-6. PMC: 6579196. View

20.

Wolk D, Zhang Z, Boudhar S, Clark C, Pontecorvo M, Arnold S . Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry. 2012; 83(9):923-6. PMC: 4479493. DOI: 10.1136/jnnp-2012-302548. View